Day: December 9, 2025

Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System’s Convertible Dual Lumen Cannula Device and Method of Use

Written by Customer Service on December 9, 2025. Posted in Public Companies.

RA’ANANA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) — Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company“), a pioneer in innovative life-support and diagnostic technologies, announced today that the Japan Patent Office has granted Patent No. 7777598. This patent covers the Company’s novel Convertible Dual Lumen Cannula device and method of use, securing exclusive rights in one of the world’s most advanced medical device markets. The patent grants Inspira exclusive commercial rights in the patented Dual Lumen Cannula technology in Japan through 2041. This milestone complements the Company’s existing U.S. Patent (granted in 2023), further enhancing a unified protective barrier across two of the world’s largest healthcare economies. Strategically,...

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Written by Customer Service on December 9, 2025. Posted in Public Companies.

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient life Barzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a large, randomized, placebo-controlled study–all primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment period (20 weeks) in Phase 2 study Initiation of EMBARQ-ColdU and SD marks second barzolvolimab Phase 3 program; Phase 3 in CSU ongoingHAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of barzolvolimab in adult patients with cold urticaria (ColdU) and symptomatic dermographism...

Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company

Written by Customer Service on December 9, 2025. Posted in Mergers And Acquisitions.

Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2.4x LTM EBITDA2 Will give Cronos #1 market share3 in the largest adult-use cannabis market in Europe Enables borderless product strategy, leveraging investments in genetics, R&D, and product development TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, is pleased to announce that its wholly-owned subsidiary has entered into a definitive share sale and purchase agreement (the “Purchase Agreement”) to acquire all of the outstanding shares of CanAdelaar B.V. (“CanAdelaar”), the largest cannabis company3 operating...

AGF Management Limited Declares Fourth Quarter 2025 Dividend

Written by Customer Service on December 9, 2025. Posted in Dividend Reports And Estimates.

TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) — On December 8, 2025, the Board of Directors of AGF Management Limited declared a dividend of 12.5 cents per share on both the Class B Non-Voting shares and the Class A Voting common shares of the company. This dividend will be payable on January 15, 2026 to shareholders of record on January 7, 2026. About AGF Management Limited Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth. AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental,...

ZenaTech Enters UK Market Closing Drone-as-a-Service Acquisition of Casado Design Ltd., Expanding to the Growing Telecom Tower Design and Infrastructure Sector

Written by Customer Service on December 9, 2025. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology business solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces the acquisition of Casado Design Ltd., a survey and design company located in the South West of England with a strong reputation and expertise in 3D modeling and scanning services for tower and infrastructure building in the telecom sector. This acquisition marks the entry of Drone as a Service to the UK and the company’s expansion into telecom infrastructure, an area experiencing new investment and transformation in the UK and across Europe. “Acquiring Casado Design is an important milestone expanding our Drone as...

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Written by Customer Service on December 9, 2025. Posted in Public Companies.

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ianalumab plus eltrombopag achieved sustained platelet response at six months compared to 39% with placebo plus eltrombopag1,2Ianalumab, administered as four once-monthly intravenous doses in the ITP setting, has the potential to reduce the need for chronic treatment and deliver durable disease control in ITPNovartis plans to submit VAYHIT2 data from second-line ITP with results from ongoing first-line ITP trial, VAYHIT1, to health authorities in 2027Basel, December 9, 2025 – Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia...

Parex Resources Announces Update on Discussions with GeoPark Regarding a Potential Business Combination

Written by Customer Service on December 9, 2025. Posted in Mergers And Acquisitions.

CALGARY, Alberta, Dec. 09, 2025 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) today announced that it has halted discussions with GeoPark Limited (“GeoPark”) (NYSE: GPRK) regarding the acquisition of GeoPark by Parex. Based on Parex’s review of information provided by GeoPark since November 14, 2025, as well as virtual and in-person discussions with GeoPark management, Parex has determined that there is no basis to increase its view on the value of GeoPark common shares relative to the proposal to acquire all GeoPark shares for US$9.00 per share in cash, which Parex submitted to the GeoPark board of directors on September 4, 2025 (the “September Proposal”). Following its engagement with Geopark over the past month, Parex concluded, given the gap in perceived value, that further discussions were unlikely...

G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results and Updates Fiscal 2026 Outlook; Initiates First Ever Quarterly Dividend Program

Written by Customer Service on December 9, 2025. Posted in Dividend Reports And Estimates.

Net Income Per Diluted Share of $1.84 and Non-GAAP Net Income Per Diluted Share of $1.90 for the Third Quarter, Both Exceeding Guidance Net Sales of $988.6 Million for the Third Quarter Raises GAAP and Non-GAAP Net Income Per Diluted Share Guidance Maintains Strong Cash and Availability Position Introduces First Ever Quarterly Dividend of $0.10 Per ShareNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — G-III Apparel Group, Ltd. (NasdaqGS: GIII) (“G-III” or the “Company”) today reported results for the third quarter of fiscal 2026, ended October 31, 2025 and announces approval of a quarterly dividend. Morris Goldfarb, G-III’s Chairman and Chief Executive Officer, said, “We delivered a strong third quarter with gross margins and earnings far exceeding our expectations. This was driven by the strength of our go-forward portfolio, particularly...

Exodus Movement, Inc. November 2025 Treasury Update and Monthly Metrics

Written by Customer Service on December 9, 2025. Posted in Public Companies.

Digital asset holdings facilitate Exodus’ agreement to acquire W3C OMAHA, Neb., Dec. 09, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus’ corporate treasury, as well as updated user and exchange provider processed volume metrics, as of November 30, 2025: Selected Digital Asset Holdings (Unaudited)Bitcoin (BTC): 1,902 BTC as of November 30, 2025, compared to 2,147 BTC as of October 31, 2025.Of the 1,902 BTC held as of November 30, 2025, 1,116 BTC is pledged as collateral under the Company’s credit facility with Galaxy Digital.Ethereum (ETH): 2,802 ETH as of November 30, 2025 compared to 2,784 as of October 31, 2025.Solana (SOL): 31,050 SOL as of November...

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

Written by Customer Service on December 9, 2025. Posted in Public Companies.

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206 Strong early partnering interest underscores industry confidence in Formycon’s biosimilar expertise and development excellence Agreement structure includes in total mid-teens-million-euro upfront and 2025 milestone payments, alongside additional development and regulatory milestones and a mid-double-digit-gross-profit-share upon launch Clinical development phase of FYB206 nearly completed; primary endpoint data expected in the first quarter of 2026PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) — Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today...

Day: December 9, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals